Treatment sequence in elderly metastatic castration-resistant prostate cancer (mCRPC) patients (pts) in a prospective cohort study.

María José Méndez-Vidal,Rebeca Lozano,Elena Castro,Nuria Romero Laorden,Alejo Rodriguez-Vida,Nuria Lainez,Amaia Hernández,R. Villatoro,Francisco Zambrana,Jose Carlos Villa Guzman,Rocío García-Domínguez,Saray Galván-Ruíz,Ricardo Escribano,Enrique Gallardo Diaz,Rosa Querol,Raquel Luque,Aranzazu Gonzalez del Alba,Javier Puente,David Olmos,David Lorente

Treatment sequence in elderly metastatic castration-resistant prostate cancer (mCRPC) patients (pts) in a prospective cohort study.

2019

5053Background: Abiraterone (Abi), enzalutamide (Enza) and docetaxel (Doc) are all valid first-line (1L) mCRPC treatment options. SIOG guidelines (Droz, Eur Urol 2017) recommend that fit elderly pt...

Keywords:

Prostate cancer
Castration
Prospective cohort study
Oncology
Pathology
Medicine
Internal medicine
treatment options
treatment sequence
Abiraterone
castration resistant
Docetaxel
Enzalutamide
Physical therapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations